Live Breaking News & Updates on ஹனா பார்ம்

Stay updated with breaking news from ஹனா பார்ம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

​​​​​​​PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2021


​​​​​​​PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2021
DGAP-News: PAION AG
/ Key word(s): Quarterly / Interim Statement
12.05.2021 / 07:30
PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2021
- Remimazolam launches in the U.S. and South Korea in the first quarter of 2021
- EU market approval received for remimazolam in procedural sedation in March 2021
- Good progress in commercialization of remimazolam in the U.S., Japan, China and South Korea through our partners
- Expansion of European product portfolio with GIAPREZA
(R) and XERAVA
- Successful rights issue of EUR 7.8 million completed in April 2021
- Revenues of EUR 3.2 million ....

United Kingdom , South Korea , Hana Pharm , Ralf Penner , Jim Phillips , Jolla Pharmaceutical Company , International Financial Reporting Standards , European Commission , Frankfurt Stock Exchange , Regulatory Agency , Distribution Services , European Investment Bank , Interim Statement , Prime Standard , European Economic Area , United Kingdom Medicines , Acacia Pharma , Western Europe , Authorized Capital , Corporate News , Regulatory Announcements , ஒன்றுபட்டது கிஂக்டம் , தெற்கு கொரியா , ஹனா பார்ம் , ரால்ஃப் பென்னர் , ஜிம் பிலிப்ஸ் ,

PAION ANNOUNCES PRODUCT LAUNCH OF BYFAVO (REMIMAZOLAM) IN SOUTH KOREA BY HANA PHARM


PAION ANNOUNCES PRODUCT LAUNCH OF BYFAVO (REMIMAZOLAM) IN SOUTH KOREA BY HANA PHARM
DGAP-News: PAION AG
/ Key word(s): Market launch
07.04.2021 / 09:00
PAION ANNOUNCES PRODUCT LAUNCH OF BYFAVO
TM (REMIMAZOLAM) IN SOUTH KOREA BY HANA PHARM
Aachen (Germany), 07 April 2021 - The Specialty Pharma Company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard) today announces that Hana Pharm, remimazolam licensee for South Korea, informed PAION about the launch of Byfavo
TM (remimazolam) for the use in general anesthesia in South Korea.
Remimazolam was approved in South Korea for general anesthesia in January 2021 and will be marketed under the brand name Byfavo ....

South Korea , South Korean , Yichang Humanwell , Hana Pharm , Ralf Penner , Jim Phillips , Specialty Pharma Company , Frankfurt Stock Exchange Prime Standard , Distribution Services , Chief Executive Officer , Acacia Pharma , Southeast Asia , Western Europe , Corporate News , Regulatory Announcements , தெற்கு கொரியா , தெற்கு கொரியன் , ஹனா பார்ம் , ரால்ஃப் பென்னர் , ஜிம் பிலிப்ஸ் , சிறப்பு பார்மா நிறுவனம் , பிராங்க்ஃபர்ட் ஸ்டாக் பரிமாற்றம் ப்ரைம் தரநிலை , விநியோகம் சேவைகள் , தலைமை நிர்வாகி அதிகாரி , தென்கிழக்கு ஆசியா , மேற்கு யூரோப் ,